Seeking Alpha

InterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet...

InterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet even earlier than expected. FDA rejected the drug in May, sending shares off a cliff. Esbriet would be the first effective treatment for the fatal disease idiopathic pulmonary fibrosis.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector